BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.63, $0.46 better than the analyst estimate of $0.17. Revenue for the quarter came in at $519 million versus the consensus estimate of $507.52 million.

GUIDANCE:

BioMarin Pharma sees FY2022 revenue of $2.05-2.15 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.